Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

AXCELLA HEALTH INC.

(AXLA)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
07/20/2021 07/21/2021 07/22/2021 07/23/2021 07/26/2021 Date
3.54(c) 3.83(c) 3.67(c) 3.57(c) 3.46(c) Last
116 448 126 067 60 393 58 410 92 338 Volume
+1.14% +8.19% -4.18% -2.72% -3.08% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 - - -
Net income 2021 -68,7 M - -
Net cash position 2021 15,6 M - -
P/E ratio 2021 -1,96x
Yield 2021 -
Sales 2022 - - -
Net income 2022 -82,2 M - -
Net Debt 2022 3,04 M - -
P/E ratio 2022 -1,61x
Yield 2022 -
Capitalization 131 M 131 M -
EV / Sales 2021 -
EV / Sales 2022 -
Nbr of Employees 59
Free-Float 76,4%
More Financials
Company
Axcella Health Inc. is a biotechnology company. The Company focuses on research and development of multifactorial interventions to support health and address dysregulated metabolism across a spectrum of consumers. It designs and develops endogenous metabolic modulators. Its AXA Development Platform produces a pipeline of AXA candidates with programs in liver, muscle and blood. The CompanyÔÇÖs wholly owned pipeline... 
More about the company
Ratings of Axcella Health Inc.
Trading Rating : 
Investor Rating :  -
ESG Refinitiv : 
D+
More Ratings
All news about AXCELLA HEALTH INC.
07/22AXCELLA : to Report Second Quarter 2021 Financial Results on July 29, 2021
BU
07/06SECTOR UPDATE : Health Care Stocks Sit Out Recovery As Biotechs Weigh
MT
07/06SECTOR UPDATE : Health Care Stocks Under the Weather
MT
07/06Wall Street Set for Flat Open as Traders Return from Long Holiday Weekend
MT
07/06AXCELLA HEALTH : HC Wainwright Starts Axcella Health at Buy With $14 Price Targe..
MT
06/30AXCELLA HEALTH : Starts Phase 2 Trial of Treatment for Recurrent Overt Hepatic E..
MT
06/30AXCELLA : Announces Initiation of EMMPOWER℠ Phase 2 Clinical Trial of AXA1..
BU
06/30Axcella Announces Initiation of EMMPOWER Phase 2 Clinical Trial of AXA1665
CI
06/25AXCELLA HEALTH INC.(NASDAQGM : AXLA) dropped from Russell 3000E Value Index
CI
06/25AXCELLA HEALTH INC.(NASDAQGM : AXLA) dropped from Russell 2500 Growth Index
CI
06/25AXCELLA HEALTH INC.(NASDAQGM : AXLA) dropped from Russell 3000E Index
CI
06/25AXCELLA HEALTH INC.(NASDAQGM : AXLA) dropped from Russell 2000 Index
CI
06/25AXCELLA HEALTH INC.(NASDAQGM : AXLA) dropped from Russell Small Cap Comp Growth ..
CI
06/25AXCELLA HEALTH INC.(NASDAQGM : AXLA) dropped from Russell 3000 Value Index
CI
06/25AXCELLA HEALTH INC.(NASDAQGM : AXLA) dropped from Russell 2500 Index
CI
More news
News in other languages on AXCELLA HEALTH INC.

- No features available -

More news
Analyst Recommendations on AXCELLA HEALTH INC.
More recommendations
Chart AXCELLA HEALTH INC.
Duration : Period :
Axcella Health Inc. Technical Analysis Chart | AXLA | US05454B1052 | MarketScreener
Technical analysis trends AXCELLA HEALTH INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 9
Last Close Price 3,46 $
Average target price 14,88 $
Spread / Average Target 330%
EPS Revisions
Managers and Directors
William R. Hinshaw President, Chief Executive Officer & Director
Laurent Chardonnet Chief Financial Officer & Senior Vice President
David R. Epstein Chairman
Tony Tramontin Chief Scientific Officer, Senior VP-R&D
Alison Schecter President-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
AXCELLA HEALTH INC.-33.33%131
GILEAD SCIENCES, INC.18.01%86 563
BIONTECH SE251.15%69 138
WUXI APPTEC CO., LTD.32.49%67 035
REGENERON PHARMACEUTICALS19.60%59 833
VERTEX PHARMACEUTICALS-15.83%51 496